Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30648568 | 1.00 | KDM4E (0.57) | KDM4ESTAT3HIF1APRKAG1PRKAA1 | |
| SCHEMBL27956751 | 0.89 | KDM4E (0.57) | KDM4ESTAT3HIF1AGSK3BTRPA1 | |
| SCHEMBL1573096 | 0.86 | PRKAG1 (0.58) | KDM4EPRKAG1PRKAA1PRKAB1GSK3B | |
| SCHEMBL4794844 | 0.86 | KDM4E (0.63) | KDM4ESTAT3HIF1APRKAG1PRKAA1 | |
| SCHEMBL27837474 | 0.85 | NTRK1 (0.44) | KDM4EPRKAG1PRKAA1PRKAB1GSK3B | |
| SCHEMBL12583332 | 0.84 | GSK3B (0.49) | KDM4EGSK3BGAAKMT2A | |
| SCHEMBL27956758 | 0.82 | KDM4E (0.58) | KDM4ESTAT3HIF1APRKAG1PRKAA1 | |
| SCHEMBL2536370 | 0.80 | KDM4E (0.63) | KDM4ESTAT3HIF1APRKAG1PRKAA1 | |
| SCHEMBL173308 | 0.79 | KDM4E (0.65) | KDM4ESTAT3HIF1APRKAG1PRKAA1 | |
| SCHEMBL4793050 | 0.79 | KDM4E (0.65) | KDM4ESTAT3HIF1APRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304113-A | Synthesis method of 5- (trifluoromethoxy) -1H-indazole-3-carboxylic acid methyl ester | 南通大学 | 2023-12-29 | — | — | CN | claimed |
| CN-117304113-A | Synthesis method of 5- (trifluoromethoxy) -1H-indazole-3-carboxylic acid methyl ester | 南通大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-117304113-A | Synthesis method of 5- (trifluoromethoxy) -1H-indazole-3-carboxylic acid methyl ester | 南通大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-117304113-A | Synthesis method of 5- (trifluoromethoxy) -1H-indazole-3-carboxylic acid methyl ester | 南通大学 | 2023-12-29 | — | — | CN | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-1937647-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036727-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036727-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | KDM4E 540/4885STAT3 532/4885HIF1A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.